Source: Virtual Congress 2021 – Environmental and lifestyle impacts on chronic lung disease



Rating:

Share or cite this content

Citations should be made in the following way:
M. Ostrovskyy (Ivano-Frankivsk, Ukraine), N. Korzh (Ivano-Frankivsk, Ukraine), G. Korzh (Ivano-Frankivsk, Ukraine), K. Ostrovska (Ivano-Frankivsk, Ukraine), M. Kulynych-Miskiv (Ivano-Frankivsk, Ukraine), O. Varunkiv (Ivano-Frankivsk, Ukraine), I. Savelikhina (Ivano-Frankivsk, Ukraine), K. Shvets (Ivano-Frankivsk, Ukraine). Dynamics of marker of inflammation - sICAM-1 in the process of treatment of COPD GOLD III destabilization phase in overweight patients.. 2330

Member's Comments

No comment yet.

Related content which might interest you: Relationship between endothelial dysfunction and GOLD stage in patients with COPD Source: International Congress 2016 – Prevalence, prognosis, and risk factors of COPD Year: 2016 The diagnostic value of leptin in progression of GOLD III COPD in patients with excessive body weight Source: Virtual Congress 2021 – Environmental and lifestyle impacts on chronic lung disease Year: 2021 Prevalence of small airway dysfunction among GOLD stages in COPD patients Source: International Congress 2016 – Functional assessment of the airways Year: 2016 Serum levels of a MMP-12 generated type IV collagen fragment is elevated in COPD and IPF patients Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 Increased circulating alveolar epithelial microparticles in COPD patients Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Advanced glycation end product (AGE), soluble receptor for AGE (sRAGE) and inflammation in smokers and mild/moderate chronic obstructive pulmonary disease (COPD) Source: International Congress 2015 – Functional capacity, exercise and pulmonary rehabilitation in chronic lung diseases Year: 2015 Elevated circulating CTLA-4 level in patients with COPD is related to systemic inflammation and disease severity Source: Annual Congress 2013 –COPD: markers and inflammation Year: 2013 Heterogeneity of group D in the new GOLD classification of COPD Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014 The effect of smoking on the activity of inflammatory markers in patients with COPD Source: Annual Congress 2013 –Tobacco use in different countries: crisis to disease Year: 2013 Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE) Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Identification of oxidative stress markers and their association with inflammation in smokers and early chronic obstructive pulmonary disease (COPD) Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases Year: 2016 The role of determining the levels of collagen type IV in the management of patients with severe chronic obstructive pulmonary disease – Focus on roflumilast Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Altered expression of glycosaminoglycans in the BAL of COPD patients with acute exacerbation Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench Year: 2013 Cardiovascular comorbidities prevails in the early stages of COPD irrespective of predominant airway or emphysema phenotype Source: Annual Congress 2013 –COPD treatment Year: 2013 Three year follow-up of distribution and stability of patients with COPD according GOLD 2014 Source: International Congress 2015 – Clinical assessment in asthma and COPD Year: 2015 Role of matrix metalloproteinase in predicting of COPD stability Source: International Congress 2015 – COPD: notable points Year: 2015 Differences in the polarization of the inflammatory response of patients with chronic obstructive pulmonary disease (COPD) secondary to smoking and to biomass smoke exposure Source: Annual Congress 2013 –COPD: new markers of diseases Year: 2013 Plasma levels of TIPM-2 in patients with COPD Source: International Congress 2016 – Molecular targets in pulmonary disease Year: 2016 Proteinase-inhibitor system state in patients with COPD Source: International Congress 2015 – COPD: chronic disease and comorbidities Year: 2015